The conceptual class of TTP-L Inhibitors encompasses a range of compounds that, through their action on various signaling molecules and pathways, possess the potential to indirectly modulate the activity or expression of TTP-L. Given TTP-L's presumed involvement in critical cellular processes, the selected inhibitors target key regulatory mechanisms that influence gene expression, mRNA stability, and protein synthesis. This approach highlights the complexity of targeting proteins indirectly through the modulation of broader cellular processes and underscores the potential for strategic intervention in pathways that regulate the function of proteins implicated in transcriptional or post-transcriptional regulation.
By focusing on compounds that can influence the cellular context in which TTP-L operates, this strategy provides a means to explore the biological functions of TTP-L and its role in cellular signaling and response mechanisms. Through such exploration, the selected compounds not only facilitate a deeper understanding of TTP-L's involvement in cellular processes but also exemplify broader principles of drug action and the potential of targeted chemical intervention to influence the activity of proteins critical to cellular regulation. This methodology underscores the value of indirect modulation as a strategy for investigating and potentially targeting proteins associated with key biological functions, offering a foundation for further research into the mechanisms of action of TTP-L and the development of novel approaches to modulate its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Interferes with DNA-dependent RNA synthesis, potentially affecting TTP-L related mRNA stability. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Inhibits protein biosynthesis, could indirectly affect TTP-L function by blocking translation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor, could alter signaling pathways that regulate TTP-L activity or expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor, might modulate stress response pathways associated with TTP-L regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor, could disrupt signaling pathways that influence TTP-L activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Proteasome inhibitor, may indirectly affect TTP-L by altering protein degradation pathways. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
BET bromodomain inhibitor, potentially influencing transcription factors regulating TTP-L expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNMT inhibitor, might alter DNA methylation and impact TTP-L gene expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
HDAC inhibitor, could affect chromatin structure and gene expression relevant to TTP-L. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor, might influence TTP-L activity through altered protein turnover. | ||||||